Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valaciclovir Dosing in Primary CMV Infection in Pregnancy
2023-508643-46-00Phase 2Authorised
- Sponsor
- Institute of Mother and Child
- Start
- Feb 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of valaciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Institute of Mother and Child. Primary endpoint: Absence of CMV DNA in amniotic fluid. Planned start Feb 2024; status: authorised.
02
Drugs
valaciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2023-508643-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508643-46-00.